Megadose drug combination - Cell Source

Drug Profile

Megadose drug combination - Cell Source

Latest Information Update: 21 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Source
  • Developer The University of Parma
  • Class Stem cell therapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Bone marrow transplant rejection

Most Recent Events

  • 11 Nov 2015 Cell Source plans a phase I/II trial in Transplant rejection in Germany and Italy
  • 01 Jul 2015 Phase I trials in Bone marrow transplant rejection in Italy (IV)
  • 01 Apr 2014 Cell Source amends license related to Megadose platform with Yeda Research and Development (Cell Source, Form 8-k, June 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top